Latest Articles

Statin/Ezetimibe Combination VS Statin Monotherapy

Evaluation of lipid management following ACS

Event rates and Risk Factors for Recurrent CV Events

ESC Lp(a) in Clinical practice EAS Consensus statement

Unmet clinical needs in the management of VTE in at-risk patients

LDL-C in the management of high cardiovascular risk, changing the paradigm for prevention

The European experience: Swedeheart and AIFA registries

Highlights on the most recent real-world data on the use of PCSK9 inhibitors, including those from the Swedeheart and AIFA registries.

Why compromise for less: Should PCSK9 inhibitors be initial therapy?

What do us physicians and patients think about LLTs and goals of treatment?

Physician and patient perceptions of benefits, risks, and treatment goals of lipid-lowering therapy: Results from GOULD registry.